Brian Druker
MD
Director, Knight Cancer Institute; JELD-WEN Chair in Leukemia Research
👥Biography 个人简介
Brian Druker led the clinical development of imatinib (Gleevec/STI571) for chronic myeloid leukemia, translating the discovery of BCR-ABL into one of the most transformative cancer treatments ever created. The IRIS trial he led demonstrated that imatinib achieved complete cytogenetic remission in the vast majority of CML patients, fundamentally changing the disease from a fatal to a manageable chronic condition. He is widely regarded as a founding father of targeted cancer therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Brian Druker 的研究动态
Follow Brian Druker's research updates
留下邮箱，当我们发布与 Brian Druker（Oregon Health and Science University (OHSU)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment